Selvita S.A. announced completion of the construction of its new headquarters in Krakow, Poland. The newly built Selvita Research Centre is expected to strengthen Selvita's ability to provide top-notch research services in the field of drug discovery. This facility constitutes a key element of Selvita's Development Strategy for 2022-2025, putting a great emphasis on Company's further organic growth.

The completion of the construction marks a significant milestone in Selvita's development journey. Selvita plans to move part of its drug discovery activities to the new site, which is located in close proximity to the current company's facilities. Following the move, Selvita will be able to expand its operations also in drug development and analytical testing in the research space made available at its hitherto location.

Almost 4,000 m2 of the new laboratory space has been designed to meet the highest industry standards and latest regulations, providing a safe and efficient environment, fostering scientific innovation. At the core of the new Selvita facility is a wide range of drug discovery laboratories, including medicinal chemistry, biochemistry, in vitro biology, ADME/DMPK, and in vivo pharmacology. Equipped with cutting-edge technology platforms and equipment, the company is able to offer an even more comprehensive range of services, covering all stages of drug discovery, from target validation to clinical candidate selection.

Within the broad scope of services executed in the new building, Selvita will continue developing its in vivo platform dedicated to oncology and immunooncology, which is a great addition to its long-term expertise in these therapeutic areas. With a capacity to accommodate around 250 scientists, the investment represents a deep confidence in the company's future development.